Associated Papers
Genetic polymorphisms in ABCB1 are correlated with the increased risk of atorvastatin-induced muscle side effects: a cross-sectional study.
Lalatović N et al.
Scientific Reports, 2023
SLCO1A2, SLCO1B1 and SLCO2B1 polymorphisms influences chloroquine and primaquine treatment in Plasmodium vivax malaria.
Sortica VA et al.
Pharmacogenomics, 2017
28975866 (PubMed )
Supplement: pgs-18-1401-s1.docx
Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.
Arrigoni E et al.
International Journal of Molecular Sciences, 2017
Causes and Consequences of Variability in Drug Transporter Activity in Pediatric Drug Therapy.
Rodieux F et al.
Journal of Clinical Pharmacology, 2016
Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.
Lai Y et al.
Expert Opinion on Drug Metabolism & Toxicology, 2012
Impact of MDR1 haplotypes derived from C1236T, G2677T/A and C3435T on the pharmacokinetics of single-dose oral digoxin in healthy Chinese volunteers.
Xu P et al.
Pharmacology, 2008
Genetic polymorphisms of drug transporters: pharmacokinetic and pharmacodynamic consequences in pharmacotherapy.
Ieiri I et al.
Expert Opinion on Drug Metabolism & Toxicology, 2006
Implications of genetic polymorphisms in drug transporters for pharmacotherapy.
Kerb R
Cancer Letters, 2006
A variant 2677A allele of the MDR1 gene affects fexofenadine disposition.
Yi SY et al.
Clinical Pharmacology and Therapeutics, 2004
The MDR1 (ABCB1) gene polymorphism and its clinical implications.
Ieiri I et al.
Clinical Pharmacokinetics, 2004
MDR1 genotype-related pharmacokinetics and pharmacodynamics.
Sakaeda T et al.
Biological & Pharmaceutical Bulletin, 2002
Select a paper to view details